EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo‐controlled multiomics‐based clinical trial

Fernanda Cristofori iD, Francesco Maria Calabrese iD, Ilaria Iacobellis, Monica Santamaria, Giuseppe Celano, Ilario Ferrocino, Emanuela Di Sabato, Rocco Pergola, Vanessa N Dargenio, Leonardo Paulucci, Maria De Angelis, Ruggiero Francavilla

Journal of Pediatric Gastroenterology and Nutrition · 2025

DOI: 10.1002/jpn3.70154 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von Fernanda Cristofori und 11 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Department of Medicine, Pediatric Section, Children's Hospital' Giovanni XXIII', University of Bari Aldo Moro, Bari, Italy. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Gastrointestinal Microbiome, Butyric Acid, Dietary Supplements. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, and treatment involves nonpharmacological and pharmacological therapies, even if there is no optimal therapy. This randomized, placebo‐controlled, double‐blind trial aimed to evaluate the efficacy of calcium butyrate supplementation in reducing IBS symptoms and to assess its effects on gut microbiota composition and relative metabolic profiles through a multiomics approach.

Methods

Children aged 4–17 years with IBS diagnosed according to the Rome IV criteria were randomized to receive either a formulation based on calcium butyrate (500 mg/day) or placebo for 8 weeks, followed by a 4‐week follow‐up period. Clinical assessments included the visual analogue scale (VAS) and gastrointestinal symptom rating scale (GSRS). Fecal samples were analyzed via 16S metataxonomics and targeted/untargeted metabolomics. The primary outcome was an ≥50% reduction in the VAS scores. Secondary outcomes included microbiota composition changes and metabolite profile alterations.

Results

Fifty‐one children were enrolled. Treatment success was significantly higher in the butyrate group (73% vs. 3.8%, p < 0.0001). VAS and GSRS scores were significantly reduced in butyrate‐treated patients at the end of treatment and postwashout. Metataxonomic analysis revealed increased short chain fatty acids‐producing bacteria, including Lachnospiraceae and Ruminococcus gauvreauii , while pro‐inflammatory taxa such as Ruminococcus gnavus decreased. Metabolomics confirmed significant changes in SCFA and VOCs, supporting microbiota modulation.

Discussion

Calcium butyrate supplementation effectively reduced IBS symptoms and induced beneficial microbiota and metabolic shifts in pediatric patients. These findings support butyrate as a potential therapy in pediatric IBS, warranting further large‐scale investigations to confirm efficacy and optimize dosing strategies. Clinical Trial Identification Number Study registered on: https://ClinicalTrials.gov . Number of registration: NCT04566679 Date of registration: 28/09/2020. Date of first enrollment of patients: 01/05/2021.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeGastrointestinal MicrobiomeButyric AcidDietary SupplementsButyratesHumansChildMaleFemaleAdolescentDouble-Blind MethodChild, PreschoolTreatment OutcomeFecesMultiomics

Stichwörter der Autor:innen

16S sequencingSCFAsfecal metabolomicsgut homeostasisintestinal microbiota

Substanzen

Butyric AcidButyrates

Autor:innen und Institutionen

  • Interdisciplinary Department of Medicine, Pediatric Section, Children's Hospital' Giovanni XXIII', University of Bari Aldo Moro, Bari, Italy.
  • Department of Soil, Plant and Food Sciences, University of Bari Aldo Moro, Bari, Italy.
  • Department of Agricultural, Forest and Food Sciences, University of Turin, Grugliasco, Italy.

ORCID-Profile: Fernanda Cristofori, Francesco Maria Calabrese

Förderung

  • None

Zitieren

APA

Cristofori, F., Calabrese, F. M., Iacobellis, I., Santamaria, M., Celano, G., Ferrocino, I., Di Sabato, E., Pergola, R., Dargenio, V. N., Paulucci, L., De Angelis, M., & Francavilla, R. (2025). Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo‐controlled multiomics‐based clinical trial. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70154

Vancouver

Cristofori F, Calabrese FM, Iacobellis I, Santamaria M, Celano G, Ferrocino I, et al. Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo‐controlled multiomics‐based clinical trial. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.70154

BibTeX
@article{Cristofori2025,
  author = {Cristofori, Fernanda and Calabrese, Francesco Maria and Iacobellis, Ilaria and Santamaria, Monica and Celano, Giuseppe and Ferrocino, Ilario and Di Sabato, Emanuela and Pergola, Rocco and Dargenio, Vanessa N and Paulucci, Leonardo and De Angelis, Maria and Francavilla, Ruggiero},
  title = {Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo‐controlled multiomics‐based clinical trial},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2025},
  doi = {10.1002/jpn3.70154}
}
Kostenlos starten →